Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 39th Annual Strategic Decisions Conference on May 31st at the New York Hilton Midtown. Joaquin Duato, Chairman of the Board and CEO, will represent the company in a session scheduled for 10:00 a.m. (Eastern Time).
This event will be accessible to investors and interested parties via the Johnson & Johnson website at www.investor.jnj.com. A replay of the webcast will be available approximately 48 hours after the live session.